| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Monday.
Shares of BioAge Labs, Inc. (NASDAQ:BIOA) fell sharply in today's pre-market trading after the company announced discontinuation of STRIDES Phase 2 clinical trial evaluating Azelaprag in combination with Tirzepatide for the treatment of obesity.
BioAge Labs shares tumbled 68.6% to $6.30 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
Now Read This: